NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis today announced a €1.9 million ($2.5 million) subsidy from the Flemish government for the development of diagnostic cancer tests.

The funding is for a two-year period, during which Biocartis will develop tests to run on its fully automated system. The tests will be directed at the detection of known, validated oncogenes "and allow for more targeted treatment of certain cancers," Biocartis said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.